GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » Net Current Asset Value

Hualan Biological Engineering (SZSE:002007) Net Current Asset Value : ¥3.33 (As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Hualan Biological Engineering Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Hualan Biological Engineering's net current asset value per share for the quarter that ended in Mar. 2025 was ¥3.33.

The historical rank and industry rank for Hualan Biological Engineering's Net Current Asset Value or its related term are showing as below:

SZSE:002007' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.66   Med: 10.57   Max: 22.09
Current: 4.83

During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Hualan Biological Engineering was 22.09. The lowest was 4.66. And the median was 10.57.

SZSE:002007's Price-to-Net-Current-Asset-Value is ranked worse than
58.55% of 982 companies
in the Biotechnology industry
Industry Median: 3.84 vs SZSE:002007: 4.83

Hualan Biological Engineering Net Current Asset Value Historical Data

The historical data trend for Hualan Biological Engineering's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hualan Biological Engineering Net Current Asset Value Chart

Hualan Biological Engineering Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.74 2.00 2.05 2.50 2.82

Hualan Biological Engineering Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.85 2.53 2.66 2.82 3.33

Competitive Comparison of Hualan Biological Engineering's Net Current Asset Value

For the Biotechnology subindustry, Hualan Biological Engineering's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hualan Biological Engineering's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hualan Biological Engineering's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Hualan Biological Engineering's Price-to-Net-Current-Asset-Value falls into.


;
;

Hualan Biological Engineering Net Current Asset Value Calculation

Hualan Biological Engineering's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(A: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(9616.191-2463.225-1987.942-0)/1828.781
=2.82

Hualan Biological Engineering's Net Current Asset Value (NCAV) per share for the quarter that ended in Mar. 2025 is calculated as

Net Current Asset Value Per Share(Q: Mar. 2025 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(10549.824-2466.351-2000.433-0)/1827.457
=3.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hualan Biological Engineering  (SZSE:002007) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Hualan Biological Engineering Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Hualan Biological Engineering's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Hualan Biological Engineering Business Description

Traded in Other Exchanges
N/A
Address
No. 1, Hualan Avenue, Henan Province, Xinxiang, CHN, 453003
Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.
Executives
Chen Zheng Yue Executives
Fan Bei Directors, executives
Pan Ruo Wen Executives
Xie Jun Min Directors, executives
An Wen Qi Executives
An Kang Directors, executives
Ma Xiao Wei Executives
Zhang Bao Xian Executives
An Wen Jue Director
Liu Jun Executives
Wang Qi Ping Directors, executives
Lv Cheng Yu Securities Affairs Representative
Zhang Jin Gang Independent director
Wang Li Ting Independent director
Ma Li Supervisors

Hualan Biological Engineering Headlines

No Headlines